GlaxoSmithKline, Pfizer, Siemens deal

Siemens' Siemens Healthcare Diagnostics unit partnered to develop companion diagnostics for ViiV Healthcare LLC, a JV between GlaxoSmithKline and Pfizer. Siemens will develop a companion diagnostic to determine which patients would benefit from Pfizer's HIV drug Celsentri/Selzentry maraviroc for use in clinical trials. Siemens would commercialize the diagnostic. ViiV markets maraviroc, a CC chemokine receptor 5 ( CCR5) antagonist, as Celsentri in Europe and Selzentry in the U.S. for twice-daily dosing in treatment-experienced patients with CCR5-tropic HIV-1 infection. Details were not disclosed. ...